GH RESEARCH PLC DL-025 (1KA) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.042x

Based on the latest financial reports, GH RESEARCH PLC DL-025 (1KA) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-15.02 Million ≈ $-17.56 Million USD) by net assets (€359.49 Million ≈ $420.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GH RESEARCH PLC DL-025 stock valuation for the company's overall valuation and market capitalisation.

GH RESEARCH PLC DL-025 - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how GH RESEARCH PLC DL-025's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of GH RESEARCH PLC DL-025 for real-time trading data and today's change.

GH RESEARCH PLC DL-025 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GH RESEARCH PLC DL-025 ranked by their cash flow conversion efficiency. Review 1KA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Company Cash Flow Conversion Efficiency
VIA Technologies Inc
TW:2388
0.028x
Arcelik AS
IS:ARCLK
0.055x
Jiangsu Evergreen New Material Technology Inc. Co. A
SHG:603125
N/A
Grupo Televisa S.A.B
MX:TLEVISACPO
0.100x
PROG Holdings Inc
NYSE:PRG
0.222x
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
0.055x
Afry AB
ST:AFRY
0.065x
Canfor Corporation
TO:CFP
0.079x

Annual Cash Flow Conversion Efficiency for GH RESEARCH PLC DL-025 (2021–2025)

The table below shows the annual cash flow conversion efficiency of GH RESEARCH PLC DL-025 from 2021 to 2025. Also see GH RESEARCH PLC DL-025 balance sheet assets for a full breakdown of the balance sheet.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €279.70 Million
≈ $327.00 Million
€-43.55 Million
≈ $-50.92 Million
-0.156x +34.10%
2024-12-31 €178.95 Million
≈ $209.21 Million
€-42.28 Million
≈ $-49.44 Million
-0.236x -55.21%
2023-12-31 €218.97 Million
≈ $256.00 Million
€-33.34 Million
≈ $-38.97 Million
-0.152x -45.17%
2022-12-31 €249.82 Million
≈ $292.06 Million
€-26.20 Million
≈ $-30.63 Million
-0.105x -90.20%
2021-12-31 €277.18 Million
≈ $324.05 Million
€-15.28 Million
≈ $-17.87 Million
-0.055x --

About GH RESEARCH PLC DL-025

F:1KA Germany Biotechnology
Market Cap
$1.43 Billion
€1.22 Billion EUR
Market Cap Rank
#8017 Global
#1072 in Germany
Share Price
€17.80
Change (1 day)
-2.73%
52-Week Range
€10.20 - €27.00
All Time High
€27.00
About

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more